Primary endpoints
Aug 08, 2017
Cannabidiol trial; MyoKardia aims; LDL drug data
Failure of Phase II cannabidiol trial leads to loss for Zynerba Zynerba Pharmaceuticals’ phase II trial for transdermal cannabinoid candidate missed all its endpoints, as it failed to hit a single goal or show a dose response raises big doubts about the drug's prospects. This news eroded around 55% off Zynerba’s sto...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
